While molecular monitoring via specific mutations (e.g., RUNX1-RUNX1T1, CBFB-MYH11, NPM1, and CEBPA) is highly sensitive, more than 50% of AML patients lack these markers. This evidence concerns the gene CEBPA and acute myeloid leukemia.